Phase IIa trial assesses delgocitinib cream in rare skin disease
LEO Pharma has initiated the Phase IIa proof-of-concept DELTA NEXT trial to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle for mild to severe Palmoplantar Pustulosis (PPP).
“The DELTA NEXT trial in PPP represents an exciting new chapter in the clinical development journey of delgocitinib cream,” said Christophe Bourdon, Chief Executive Officer, LEO Pharma. “PPP is a disease with few treatment options that can severely affect quality of life. We are hopeful that this therapy could potentially provide much-needed help for patients suffering from this devastating condition.”
PPP is an uncommon, chronic, inflammatory, relapsing skin disease characterised by repeated episodes of sterile pustules alongside erythema, blistering and scaly skin on the palms and/or soles of the feet.
It is associated with complex T-cell activation patterns, which may be why many biologics that target individual T helper cell populations have shown limited efficacy in clinical trials.
Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor shown to inhibit the activity of all four JAKs, which are involved in inflammatory signalling.
“I’ve seen firsthand how PPP can severely disrupt patients’ lives, making it painful to walk, perform activities of daily living and impacting their ability to work,” said Dr Robert Bissonnette, international coordinating investigator (ICI) on the DELTA NEXT trial and Chairman at Innovaderm Montreal, Canada. “Despite the significant burden it places on patients, treatment options remain limited. There is a real and urgent need for effective therapies.”
Currently, delgocitinib cream is approved for adults in the EU, UK, Switzerland, and the United Arab Emirates for the treatment of moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate, and is under review in other markets, including the US.
Diana Spencer, Senior Digital Content Editor, DDW
